- Home
- NMRA vs AGIO Comparison
NMRA vs AGIO Comparison
Compare NMRA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- AGIO
- Stock Information
- Founded
- NMRA 2019
- AGIO 2007
- Country
- NMRA United States
- AGIO United States
- Employees
- NMRA N/A
- AGIO N/A
- Industry
- NMRA
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- AGIO Health Care
- Exchange
- NMRA Nasdaq
- AGIO Nasdaq
- Market Cap
- NMRA 1.7B
- AGIO 2.0B
- IPO Year
- NMRA 2023
- AGIO 2013
- Fundamental
- Price
- NMRA $2.05
- AGIO $32.42
- Analyst Decision
- NMRA Strong Buy
- AGIO Buy
- Analyst Count
- NMRA 6
- AGIO 7
- Target Price
- NMRA $20.67
- AGIO $56.33
- AVG Volume (30 Days)
- NMRA 6.3M
- AGIO 1.0M
- Earning Date
- NMRA 03-06-2025
- AGIO 02-13-2025
- Dividend Yield
- NMRA N/A
- AGIO N/A
- EPS Growth
- NMRA N/A
- AGIO N/A
- EPS
- NMRA N/A
- AGIO 11.80
- Revenue
- NMRA N/A
- AGIO $32,871,000.00
- Revenue This Year
- NMRA N/A
- AGIO $33.41
- Revenue Next Year
- NMRA N/A
- AGIO $172.14
- P/E Ratio
- NMRA N/A
- AGIO $2.75
- Revenue Growth
- NMRA N/A
- AGIO 36.79
- 52 Week Low
- NMRA $1.83
- AGIO $20.96
- 52 Week High
- NMRA $21.00
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- NMRA 20.26
- AGIO 33.53
- Support Level
- NMRA $2.12
- AGIO $32.85
- Resistance Level
- NMRA $2.44
- AGIO $35.03
- Average True Range (ATR)
- NMRA 0.39
- AGIO 1.75
- MACD
- NMRA -0.31
- AGIO 0.48
- Stochastic Oscillator
- NMRA 2.26
- AGIO 22.40
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.